MSD’s Keytruda (pembrolizumab) has been approved by the European Commission with a new six-weekly dosing schedule at 400mg, as opposed to the previous schedule of 200mg every three weeks, across all monotherapy indicatio……
Pfizer Inc. (NYSE: PFE) announced today the new serotypes included in its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia ……
Merc (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V224, the company’s investigational 25-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designatio……
Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha? (evolocumab) as the first PCSK9 inhibitor in China for……
Dec. 27, 2028-- Horizon Pharma plc(NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI? (gl……
- The first I-Mab proprietary drug candidate to enter clinical trials in the United StatesI-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development o……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
